Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11579723 | 0.90 | CA2 (0.51) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL5026807 | 0.90 | CA2 (0.70) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL10786081 | 0.90 | CA1 (0.50) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL3234851 | 0.84 | CYP3A4 (0.53) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL3294100 | 0.82 | TSHR (0.69) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL20710745 | 0.82 | CA1 (0.62) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL28395895 | 0.81 | CA2 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL28444068 | 0.81 | MEN1 (0.48) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL4431205 | 0.81 | CYP3A4 (0.50) | MEN1KMT2AGAACYP3A4L3MBTL1 | |
| SCHEMBL1059937 | 0.81 | MEN1 (0.67) | CA2CA1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106128947-B | A kind of lithographic method of multi-layer graphene | 山东赛帝格新材料有限责任公司 | 2019-01-29 | — | — | CN | claimed |
| CN-106128947-A | A kind of lithographic method of multi-layer graphene | 烟台市烯能新材料股份有限公司 | 2016-11-16 | — | — | CN | claimed |
| CN-115650883-A | Method for synthesizing aniline and its derivative by using nickel-ammonium complex as ammonia slow-release agent | 陕西师范大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-106128947-B | A kind of lithographic method of multi-layer graphene | 山东赛帝格新材料有限责任公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-106128947-A | A kind of lithographic method of multi-layer graphene | 烟台市烯能新材料股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2097428-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Mgp Biotechnologies, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055249-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1572704-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040127465-A1 | Novel phosphorus-containing derivatives | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| WO-2004055031-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-4003966-A | Selective phosphorylation process | MOBIL OIL CORPORATION (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127465-A1 | Novel phosphorus-containing derivatives | SLC34A2, SLC34A1, SLC20A1 | CA2 81/4885CA1 644/4885BCHE 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.